Tekla Life Sciences Investors (HQL) - Total Liabilities
Based on the latest financial reports, Tekla Life Sciences Investors (HQL) has total liabilities worth $1.73 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tekla Life Sciences Investors - Total Liabilities Trend (1996–2025)
This chart illustrates how Tekla Life Sciences Investors's total liabilities have evolved over time, based on quarterly financial data. See HQL current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Tekla Life Sciences Investors Competitors by Total Liabilities
The table below lists competitors of Tekla Life Sciences Investors ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Fasten Co Ltd
SHE:000890
|
China | CN¥784.10 Million |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
China | CN¥877.24 Million |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
China | CN¥2.51 Billion |
|
Levinstein Eng
TA:LEVI
|
Israel | ILA2.21 Billion |
|
Yantai Ishikawa Sealing Technology Co.Ltd.
SHE:301020
|
China | CN¥239.17 Million |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
USA | $4.81 Billion |
|
Beijing Tieke Shougang Railway Tech Co Ltd
SHG:688569
|
China | CN¥564.81 Million |
|
GFT Technologies SE
XETRA:GFT
|
Germany | €337.93 Million |
Liability Composition Analysis (1996–2025)
This chart breaks down Tekla Life Sciences Investors's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HQL market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tekla Life Sciences Investors's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual total liabilities of Tekla Life Sciences Investors from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $1.73 Million | +94.24% |
| 2024-09-30 | $888.61K | +33.23% |
| 2023-09-30 | $666.96K | -96.04% |
| 2022-09-30 | $16.82 Million | +56.56% |
| 2021-09-30 | $10.75 Million | +1705.34% |
| 2020-09-30 | $595.18K | -78.93% |
| 2019-09-30 | $2.82 Million | -5.14% |
| 2018-09-30 | $2.98 Million | +50.27% |
| 2017-09-30 | $1.98 Million | -25.50% |
| 2016-09-30 | $2.66 Million | -46.95% |
| 2015-09-30 | $5.01 Million | +564.49% |
| 2014-09-30 | $754.55K | +42.34% |
| 2013-09-30 | $530.12K | +31.00% |
| 2012-09-30 | $404.67K | -59.53% |
| 2011-09-30 | $1.00 Million | -81.48% |
| 2010-09-30 | $5.40 Million | -67.27% |
| 2009-09-30 | $16.50 Million | +415.63% |
| 2008-09-30 | $3.20 Million | +190.91% |
| 2007-09-30 | $1.10 Million | -59.26% |
| 2006-09-30 | $2.70 Million | +170.00% |
| 2005-09-30 | $1.00 Million | -23.08% |
| 2004-09-30 | $1.30 Million | -50.00% |
| 2003-09-30 | $2.60 Million | +766.67% |
| 2002-09-30 | $300.00K | -62.50% |
| 2001-09-30 | $800.00K | -42.86% |
| 1998-09-30 | $1.40 Million | +600.00% |
| 1997-09-30 | $200.00K | -66.67% |
| 1996-09-30 | $600.00K | -- |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more